Nicotine stimulates secretion of corticosterone via both CRH and AVP receptors

Journal of Neurochemistry

Volumn 120, Issue 6, 2012, Pages 1108-1116

  Lutfy, Kabirullah ^a,b   Aimiuwu, Otaren ^a   Mangubat, Michael ^a   Shin, Chang Sung ^a   Nerio, Namiko ^a   Gomez, Richard ^a   Liu, Yanjun ^a   Friedman, Theodore C ^a  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Antalarmin; Astressin; AVP; Corticosterone; CRH; Nicotine

Indexed keywords

ANTALARMIN; ARGIPRESSIN; ARGIPRESSIN RECEPTOR; ASTRESSIN; ASTRESSIN 2B; CORTICOSTERONE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR; NELIVAPTAN; NICOTINE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORTICOSTEROID RELEASE; CORTICOSTERONE BLOOD LEVEL; DRUG EFFECT; HORMONE RESPONSE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; STRESS;

ANALYSIS OF VARIANCE; ANIMALS; ARGININE VASOPRESSIN; CORTICOSTERONE; CORTICOTROPIN-RELEASING HORMONE; DRUG INTERACTIONS; INDOLES; MALE; MICE; MICE, INBRED C57BL; NICOTINE; NICOTINIC AGONISTS; PEPTIDE FRAGMENTS; PYRIMIDINES; PYRROLES; PYRROLIDINES; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; RECEPTORS, VASOPRESSIN;

MUS;

EID: 84862797399     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2011.07633.x     Document Type: Article

References (52)

1. Andersson K., Eneroth P. and Agnati L. F. (1981) Nicotine-induced increases of noradrenaline turnover in discrete noradrenaline nerve terminal systems of the hypothalamus and the median eminence of the rat and their relationship to changes in the secretion of adenohypophyseal hormones. Acta Physiol. Scand. 113, 227-231. (Pubitemid 11018613)
2. Bale T. L., Picetti R., Contarino A., Koob G. F., Vale W. W. and Lee K. F. (2002) Mice deficient for both corticotropin-releasing factor receptor 1 (CRFR1) and CRFR2 have an impaired stress response and display sexually dichotomous anxiety-like behavior. J. Neurosci. 22, 193-199. (Pubitemid 34033497)
3. Benowitz N. L. (2010) Nicotine addiction. N. Engl. J. Med. 362, 2295-2303.
4. Broadbear J. H., Winger G., Rivier J. E., Rice K. C. and Woods J. H. (2004) Corticotropin-releasing hormone antagonists, astressin B and antalarmin: differing profiles of activity in rhesus monkeys. Neuropsychopharmacology 29, 1112-1121. (Pubitemid 38670049)
5. Caggiula A. R., Epstein L. H., Antelman S. M., Saylor S. S., Perkins K. A., Knopf S. and Stiller R. (1991) Conditioned tolerance to the anorectic and corticosterone-elevating effects of nicotine. Pharmacol. Biochem. Behav. 40, 53-59.
6. Cam G. R. and Bassett J. R. (1984) Effect of prolonged exposure to nicotine and stress on the pituitary-adrenocortical response; the possibility of cross-adaptation. Pharmacol. Biochem. Behav. 20, 221-226. (Pubitemid 14167968)
7. Cam G. R., Bassett J. R. and Cairncross K. D. (1979) The action of nicotine on the pituitary-adrenal cortical axis. Arch. Int. Pharmacodyn. Ther. 237, 49-66. (Pubitemid 9175828)
8. Chen R., Lewis K. A., Perrin M. H. and Vale W. W. (1993) Expression cloning of a human corticotropin-releasing-factor receptor. Proc. Natl. Acad. Sci. U S A 90, 8967-8971. (Pubitemid 23306432)
9. Chrousos G. P. (1995) The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N. Engl. J. Med. 332, 1351-1362.
10. Chrousos G. P. and Gold P. W. (1992) The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA 267, 1244-1252.
11. Coste S. C., Kesterson R. A., Heldwein K. A. et al. (2000) Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nat. Genet. 24, 403-409. (Pubitemid 30187442)
12. Curtis A. L., Grigoriadis D. E., Page M. E., Rivier J. and Valentino R. J. (1994) Pharmacological comparison of two corticotropin-releasing factor antagonists: in vivo and in vitro studies. J. Pharmacol. Exp. Ther. 268, 359-365. (Pubitemid 24039109)
13. Davila-Garcia M. I., Musachio J. L. and Kellar K. J. (2003) Chronic nicotine administration does not increase nicotinic receptors labeled by [125I]epibatidine in adrenal gland, superior cervical ganglia, pineal or retina. J. Neurochem. 85, 1237-1246. (Pubitemid 36613272)
14. Deak T., Nguyen K. T., Ehrlich A. L. et al. (1999) The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress. Endocrinology 140, 79-86. (Pubitemid 29011144)
15. Donny E. C., Caggiula A. R., Rose C., Jacobs K. S., Mielke M. M. and Sved A. F. (2000) Differential effects of response-contingent and response-independent nicotine in rats. Eur. J. Pharmacol. 402, 231-240. (Pubitemid 30665848)
16. Fuxe K., Andersson K., Eneroth P., Harfstrand A. and Agnati L. F. (1989) Neuroendocrine actions of nicotine and of exposure to cigarette smoke: medical implications. Psychoneuroendocrinology 14, 19-41. (Pubitemid 19110829)
17. Gallagher J. P., Orozco-Cabal L. F., Liu J. and Shinnick-Gallagher P. (2008) Synaptic physiology of central CRH system. Eur. J. Pharmacol. 583, 215-225.
18. Gilbert D. G. (1979) Paradoxical tranquilizing and emotion-reducing effects of nicotine. Psychol. Bull. 86, 643-661.
19. Griebel G., Stemmelin J., Gal C. S. and Soubrie P. (2005) Non-peptide vasopressin V1b receptor antagonists as potential drugs for the treatment of stress-related disorders. Curr. Pharm. Des. 11, 1549-1559. (Pubitemid 40691451)
20. Grigoriadis D. E., Lovenberg T. W., Chalmers D. T., Liaw C. and De Souze E. B. (1996) Characterization of corticotropin-releasing factor receptor subtypes. Ann. N Y Acad. Sci. 780, 60-80. (Pubitemid 26196970)
21. Gulyas J., Rivier C., Perrin M. et al. (1995) Potent, structurally constrained agonists and competitive antagonists of corticotropinreleasing factor. Proc. Natl. Acad. Sci. U S A 92, 10575-10579.
22. Habib K. E., Weld K. P., Rice K. C. et al. (2000) Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc. Natl. Acad. Sci. USA 97, 6079-6084. (Pubitemid 30367526)
23. Heinrichs S. C., Lapsansky J., Lovenberg T. W., De Souza E. B. and Chalmers D. T. (1997) Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate anxiogenic-like behavior. Regul. Pept. 71, 15-21. (Pubitemid 27374934)
24. Hodgson R. A., Higgins G. A., Guthrie D. H., Lu S. X., Pond A. J., Mullins D. E., Guzzi M. F., Parker E. M. and Varty G. B. (2007) Comparison of the V1b antagonist SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression. Pharmacol. Biochem. Behav. 86, 431-440. (Pubitemid 46466874)
25. de Keyzer Y., Lenne F., Auzan C. et al. (1996) The pituitary V3 vasopressin receptor and the corticotroph phenotype in ectopic ACTH syndrome. J. Clin. Invest. 97, 1311-1318. (Pubitemid 26085488)
26. Kostich W. A., Chen A., Sperle K. and Largent B. L. (1998) Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: the CRF2gamma receptor. Mol. Endocrinol. 12, 1077-1085. (Pubitemid 30659035)
27. Lolait S. J., O'Carroll A. M., McBride O. W., Konig M., Morel A. and Brownstein M. J. (1992) Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus. Nature 357, 336-339.
28. Lovenberg T. W., Liaw C. W., Grigoriadis D. E., Clevenger W., Chalmers D. T., De Souza E. B. and Oltersdorf T. (1995) Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc. Natl. Acad. Sci. USA 92, 836-840.
29. Lutfy K., Brown M. C., Nerio N., Aimiuwu O., Tran B., Anghel A. and Friedman T. C. (2006) Repeated stress alters the ability of nicotine to activate the hypothalamic-pituitary-adrenal axis. J. Neurochem. 99, 1321-1327. (Pubitemid 44730088)
30. Matta S. G., Beyer H. S., McAllen K. M. and Sharp B. M. (1987) Nicotine elevates rat plasma ACTH by a central mechanism. J. Pharmacol. Exp. Ther. 243, 217-226.
31. Matta S. G., Fu Y., Valentine J. D. and Sharp B. M. (1998) Response of the hypothalamo-pituitary-adrenal axis to nicotine. Psychoneuroendocrinology 23, 103-113. (Pubitemid 28248465)
32. McCarthy J. R., Heinrichs S. C. and Grigoriadis D. E. (1999) Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications. Curr. Pharm. Des. 5, 289-315. (Pubitemid 29238994)
33. Miragaya J. R. and Harris R. B. (2008) Antagonism of corticotrophin- releasing factor receptors in the fourth ventricle modifies responses to mild but not restraint stress. Am. J. Physiol. Regul. Integr. Comp. Physiol. 295, R404-R416.
34. Morel A., O'Carroll A. M., Brownstein M. J. and Lolait S. J. (1992) Molecular cloning and expression of a rat V1a arginine vasopressin receptor. Nature 356, 523-526.
35. Muller M. B., Preil J., Renner U., Zimmermann S., Kresse A. E., Stalla G. K., Keck M. E., Holsboer F. and Wurst W. (2001) Expression of CRHR1 and CRHR2 in mouse pituitary and adrenal gland: implications for HPA system regulation. Endocrinology 142, 4150-4153. (Pubitemid 32802688)
36. Navarro-Zaragoza J., Nunez C., Laorden M. L. and Milanes M. V. (2010) Effects of corticotropin-releasing factor receptor-1 antagonists on the brain stress system responses to morphine withdrawal. Mol. Pharmacol. 77, 864-873.
37. Okada S., Shimizu T. and Yokotani K. (2003) Extrahypothalamic corticotropin-releasing hormone mediates (-)-nicotine-induced elevation of plasma corticosterone in rats. Eur. J. Pharmacol. 473, 217-223. (Pubitemid 36929887)
38. Perrin M. H., Donaldson C. J., Chen R., Lewis K. A. and Vale W. W. (1993) Cloning and functional expression of a rat brain corticotropin releasing factor (CRF) receptor. Endocrinology 133, 3058-3061. (Pubitemid 24000775)
39. Pomerleau O. F. and Pomerleau C. S. (1990) Cortisol response to a psychological stressor and/or nicotine. Pharmacol. Biochem. Behav. 36, 211-213.
40. Preil J., Muller M. B., Gesing A. et al. (2001) Regulation of the hypothalamic-pituitary-adrenocortical system in mice deficient for CRH receptors 1 and 2. Endocrinology 142, 4946-4955. (Pubitemid 33022371)
41. Rivier J., Gulyas J., Kirby D. et al. (2002) Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists. J. Med. Chem. 45, 4737-4747.
42. Rosecrans J. A. and Karin L. D. (1998) Effects of nicotine on the hypothalamic-pituitary-axis (HPA) and immune function: introduction to the Sixth Nicotine Round Table Satellite, American Society of Addiction Medicine Nicotine Dependence Meeting, November 15, 1997. Psychoneuroendocrinology 23, 95-102. (Pubitemid 28248464)
43. Ruhmann A., Bonk I., Lin C. R., Rosenfeld M. G. and Spiess J. (1998) Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): development of CRFR2beta-selective antisauvagine-30. Proc. Natl. Acad. Sci. U S A. 95, 15264-15269. (Pubitemid 29018687)
44. Serradeil-Le Gal C., Wagnon J., Simiand J. et al. (2002) Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl) -2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy- N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. J. Pharmacol. Exp. Ther. 300, 1122-1130. (Pubitemid 34165020)
45. Seyler L. E., Jr, Fertig J., Pomerleau O., Hunt D. and Parker K. (1984) The effects of smoking on ACTH and cortisol secretion. Life Sci. 34, 57-65. (Pubitemid 14215126)
46. Smith G. W., Aubry J. M., Dellu F. et al. (1998) Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 20, 1093-1102. (Pubitemid 28293127)
47. Spina M. G., Basso A. M., Zorrilla E. P., Heyser C. J., Rivier J., Vale W., Merlo-Pich E. and Koob G. F. (2000) Behavioral effects of central administration of the novel CRF antagonist astressin in rats. Neuropsychopharmacology 22, 230-239. (Pubitemid 30089533)
48. Timpl P., Spanagel R., Sillaber I. et al. (1998) Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat. Genet. 19, 162-166. (Pubitemid 28248798)
49. Tu H., Kastin A. J. and Pan W. (2007) Corticotropin-releasing hormone receptor (CRHR)1 and CRHR2 are both trafficking and signaling receptors for urocortin. Mol. Endocrinol. 21, 700-711.
50. Webster E. L., Lewis D. B., Torpy D. J., Zachman E. K., Rice K. C. and Chrousos G. P. (1996) In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology 137, 5747-5750. (Pubitemid 26423152)
51. Wilkins J. N., Carlson H. E., Van Vunakis H., Hill M. A., Gritz E. and Jarvik M. E. (1982) Nicotine from cigarette smoking increases circulating levels of cortisol, growth hormone, and prolactin in male chronic smokers. Psychopharmacology (Berl) 78, 305-308. (Pubitemid 13218563)
52. Zorrilla E. P., Tache Y. and Koob G. F. (2003) Nibbling at CRF receptor control of feeding and gastrocolonic motility. Trends Pharmacol. Sci. 24, 421-427. (Pubitemid 36952559)